LHD Logo Venous Thromboembolism Reducing the Risk DATE.

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Venous Thromboembolism: Risk Assessment and Prophylaxis
Preventing VTE in Surgical Patients. Today’s Topics The common sense science of VTE prevention Brief history of VTE prevention techniques High yield methods.
Deep venous thrombosis and pulmonary embolism in pregnancy Petr Krepelka, 2013.
Deep Vein Thrombosis and Pulmonary Embolism prophylaxis in Asian general surgical patients: is it necessary?  AMY KOK Caritas Medical Centre.
+ Deep Vein Thrombosis Common, Preventable, and potentially Fatal.
DVT PROPHYLAXIS SUNDIP PATEL 7 / 15 / BACKGROUND Deep Vein Thrombosis is a common, yet preventable peri-operative complication Highest risk in critical.
Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.
Prophylaxis of Venous Thromboembolism
Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.
Venous Thromboembolism
Deep Vein Thrombosis (DVT)
Beverley Hunt Simon Noble Hospital Acquired Venous Thromboembolism.
QAH HospitalPortsmouth Hospitals NHS Trust Venous Thromboembolism Patient Safety Study Day Simon Freathy.
The Health Roundtable 3-3c_HRT1215-Session_HANNAFORD_UNSW_NSW How many people received appropriate VTE prophylaxis? Presenter: Natalie Hannaford UNSW Innovation.
Venous ThromboEmbolism
WELCOME.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
DPT 732 SPRING 2009 S. SCHERER Deep Vein Thrombosis.
DVT/VTE Nursing Protocol (Deep Vein Thrombosis) (Venous Thromboembolism) Presented by Maribeth Desiongco MA, RN-BC 2008.
Chapter Two Venous Disease Coalition Pathogenesis and Consequences of VTE VTE Toolkit.
Deep vein thrombosis (DVT). Deep vein thrombosis (DVT) is a blood clot that develops in the deep and larger veins in one or both legs, usually in the.
DR FAROOQ AHMAD RANA ASSISTANT PROFESSOR SURGERY
Thromboembolism IT training Presentation Midwifery update Marie Lewis.
DR. ahmed Abanamy hospital DOCTOR Nazih Mohammed Alothman Vascular Surgeon.
What You Need to Know about Blood Clots. What You Need to Know About Blood Clots or Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
Total Joint Replacement
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
Thromboprophylaxis in Pregnancy and the Puerperium
1 VTE Protocol Presented by: Selina Baskins, RN Quality Coordinator.
Venous Thromboembolism
Risk assessment for VTE
Prevention of Venous Thromboembolism 8 th ACCP Guidelines Chest 2008.
Preventing Hospital Acquired Thrombosis Simon Noble Peggy Edwards.
CARDIOVASCULAR MODULE: DEEP VENOUS THROMBOSIS THROMBOPHLEBITIS Adult Medical-Surgical Nursing.
Obesity and Venous Thromboembolic Disease Angel Galvez MD PhD Oncology Specialists SC Lutheran General Hospital.
VTE Venous ThromboEmbolism. VTE – aims of this module To define the terms associated with VTE and offer maximum care to treat patients. To define the.
LIFEBLOOD THE Thrombosis CHARITY LIFEBLOOD THE Thrombosis CHARITY NICE Clinical Guideline 46.
Thrombophilia. Definition –Tendency to develop clots due to predisposing factors that may be genetically determined.
VTE Prevention In Action Interactive Case Scenarios.
Venous Thromboembolism Prophylaxis for Medical Inpatients Heather Hofmann, rev. 4/18/14 DSR2 Mini Lecture.
Cost-Consciousness Assignment Ollie Ross DSR 2. Adherence to ACP DVT prophylaxis guidelines Objective: Evaluate adherence to ACP DVT prophylaxis guidelines.
Drugs Used to Treat Thromboembolic Disorders Chapter 27 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
DVT & PE: How early can I mobilize a patient ??
Risk Assessment for VTE. Which of the following best describes you?
Prophylaxis Diagnosis Treatment Venous Thromboembolism Management.
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism 1 (RECORD 1 ) Journal Club General Surgery Rotation.
 Deep Vein Thrombosis Josh Vrona, Hunter Dolan, Erin McCann.
Low risk: young, with minor illnesses, who are to undergo operations lasting 30 min or less. Moderate risk: over 40 or with a debilitating illness who.
DVT cases.  Heparin, low molecular weight heparin, or fondaparinux are usually continued for at least five days, along with another medication called.
Venous Thromboembolism (VTE) Prophylaxis at Cesarean Section Phillip N. Rauk, MD.
By Anthony Suminiski, Jess Stone and Mitchell Richards.
Prevention of Venous Thromboembolism in Nonsurgical Patients Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Course Lecturer: Imon Rahman
One of the main causes of DVT is inactivity! When a person is inactive, your blood normally collects in the lower part of your body. (in your legs) This.
Prevention of Venous Thromboembolism in Orthopedic Surgery Patients Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy.
STAFFORDSHIRE THROMBOSIS AND ANTICOAGULATION CENTRE (STAC) PATIENT SPECIFIC DIRECTION FOR DALTEPARIN (LMWH) FOR PATIENTS WITH VENOUS THROMBO-EMBOLISM (VTE)/MECHANICAL.
Treatment of deep venous thrombosis and pulmonary embolism Anders Waage.
1 MMM October 2008 AVAIL ME Project Audit of Venous Thromboembolism Management in Middle East Hospitals Elham Mir,MD MPH Medical Affairs Clinical Operation.
Dr. Lesbia Adalgisa Rodriguez PGY3-Cook County Loyola Family Medicine Residency Program Venous Thromboembolism Prophylaxis in the Inpatient Setting.
Prevention of Venous Thromboembolism in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Outpatient DVT assessment & treatment Daniel Gilada.
VTE prophylaxis Sharif-Kashani,B.MD SBMU Preventing VTE Over 12 million people in the United States are at risk of VTE due to hospitalization for major.
Venous Thromboembolism Prophylaxis for Medical Inpatients
By: Dr. Nalaka Gunawansa
Ortho Warfarin Dosing Protocol
ANTICOAGULANTS Dr. A. Shyam Sundar. M.Pharm., Ph.D,
New Oral Anticoagulants and VTE Management
Presentation transcript:

LHD Logo Venous Thromboembolism Reducing the Risk DATE

Objectives Define venous thromboembolism Heighten awareness – the impact of VTE – the preventable nature of VTE Discuss importance of – VTE risk assessment – appropriate prescribing of prophylaxis – engaging patients Demonstrate how to assess VTE risk

Venous Thromboembolism VTE = Deep vein thrombosis (DVT) and/or pulmonary embolism (PE) DVTPE Occurs in deep veins (most commonly in legs and groin) Occurs after DVT dislodges and travels to the lungs Can cause long-term issues – ‘post-thrombotic syndrome’ (PTS) Serious complication which can lead to death PTS affects 23-60% of DVT patients within 2 years Lower-extremity DVT has 3% PE-related mortality rate Patients with PE have 30-60% chance of dying from it

What Causes VTE Virchow’s Triad = categories of factors contributing to blood clot formation Stasis Alteration in normal blood flow Endothelial Injury Injury or trauma to the inside of the blood vessel Hypercoagulability Alternation in the constitution of blood causing blood to clot more easily VIRCHOW’S TRIAD

The Impact of VTE More than 14,000 Australians develop a VTE per year More than 5,000 of them will die as a direct result VTE causes 7% of all hospital deaths VTE causes more deaths than bowel Ca and breast Ca

VTE Risk Factors

Intrinsic Risk FactorsExtrinsic Risk Factors Age > 60 yearsSignificantly reduced mobility (relative to normal state) due to injury or illness Obesity (BMI > 30kg/m 2 )Active malignancy or treatment with chemotherapy Prior history of VTEUse of HRT or oral contraception Pregnancy or post-partumSurgical intervention, particularly major orthopaedic surgery or abdominal/pelvic surgery for cancer Known thrombophilia (including inherited disorders) Active infection Varicose veinsInflammatory bowel disease

Hospitalisation Hospitalisation = ↑ risk of VTE ~ 50% of VTE cases occur during or soon after hospitalisation – 24% (surgery) – 22% (medical illness) Incidence 100 times greater in hospitalised patients than community residents

Preventing VTE

Preventability Largely preventable Shift thinking: complication vs adverse event

Assessing Risk Who should be assessed?

Assess overall VTE risk vs benefit – Assess clotting risk – Assess bleeding risk i.e. contraindications to prophylaxis and/or other bleeding risks Assessing Risk

Prescribing Prophylaxis Patient at risk + nil C/I = prescribe Two types of prophylaxis: 1. pharmacological 2. mechanical Ensure C/I to both pharmacological and mechanical prophylaxis have been considered Evidence-based guidelines

NHMRC Guidelines

Pharmacological Prophylaxis Anticoagulants Alter the process of blood coagulation to prevent VTE formation a9e5-ae55b11e0413%7D/new-oral-anticoagulants-for-thromboprophylaxis-after- total-hip-or-knee-arthroplasty The coagulation cascade and activity of anticoagulants

Pharmacological Prophylaxis Main anticoagulants include: Drug ClassAgents Unfractionated heparin Preferred in patients with renal impairment LMWHEnoxaparin Dalteparin Most commonly used agents Require dosage adjustment in renal impairment Factor Xa inhibitors Apixaban Rivaroxaban Alternative for prophylaxis in post- hip or knee replacement FondaparinuxAlternative for prophylaxis in post- hip or knee replacement and hip fracture surgery Direct thrombin inhibitors DabigatranAlternative for prophylaxis in prophylaxis post- hip or knee replacement HeparinoidDanaparoidUsed in heparin-sensitivity or HIT

Pharmacological Prophylaxis Contraindications may include: Other relative contraindications may exist – weigh risk vs benefit Contraindications Active bleeding Thrombocytopenia (platelets < 50 x 10 9 /L) End stage liver disease (INR > 1.5) Treatment with therapeutic anticoagulant e.g. warfarin with INR > 2 Severe trauma to head or spinal cord, with haemorrhage in last 4 weeks

Mechanical Prophylaxis Devices that increase blood flow velocity in leg veins, reducing venous stasis. They include: Device Graduated Compression Stockings (GCS) Provide graduated compression, which is firmest at the ankle. Used mainly for ambulant patients Anti-embolic StockingStandard compression throughout. Used for bedbound or non-ambulant patients Intermittent Pneumatic Compression Device (IPC) Inflatable garment wrapped around legs which is inflated by pneumatic pump. Enhances venous return Foot Impulse Device (FID)Stimulates legs veins to mimic walking and reduce stasis. Used for immobilised patients

Mechanical Prophylaxis Contraindications may include: Contraindications Skin ulceration Lower leg trauma Morbid obesity (where correct fitting of stocking cannot be achieved) Massive leg oedema or pulmonary oedema due to CCF Stroke patients (avoid compression stockings)

Other Ways to Help Prevent VTE

Empowering Patients Engage your patients

Questions For further information: